Cotinga Pharmaceuticals Inc.
COTQF
$0.0001
$0.000.00%
OTC PK
| 01/31/2020 | 10/31/2019 | 07/31/2019 | 04/30/2019 | 01/31/2019 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -80.12% | -74.05% | -61.63% |
| Gross Profit | -- | -- | 80.12% | 74.05% | 61.63% |
| SG&A Expenses | -- | -- | -51.30% | -50.23% | -37.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -63.81% | -60.58% | -48.10% |
| Operating Income | -- | -- | 63.81% | 60.58% | 48.10% |
| Income Before Tax | -- | -- | 61.76% | 46.90% | 36.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 61.76% | 46.90% | 36.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 61.76% | 46.90% | 36.30% |
| EBIT | -- | -- | 63.81% | 60.58% | 48.10% |
| EBITDA | -- | -- | 64.34% | 61.07% | 48.05% |
| EPS Basic | -- | -- | 70.58% | 60.98% | 47.93% |
| Normalized Basic EPS | -- | -- | 73.13% | 63.81% | 48.04% |
| EPS Diluted | -- | -- | 70.58% | 60.98% | 47.93% |
| Normalized Diluted EPS | -- | -- | 73.13% | 63.81% | 48.04% |
| Average Basic Shares Outstanding | -- | -- | 24.49% | 37.87% | 32.85% |
| Average Diluted Shares Outstanding | -- | -- | 24.49% | 37.87% | 32.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |